| pubmed-article:8814098 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8814098 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8814098 | lifeskim:mentions | umls-concept:C0014544 | lld:lifeskim |
| pubmed-article:8814098 | lifeskim:mentions | umls-concept:C0064636 | lld:lifeskim |
| pubmed-article:8814098 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:8814098 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8814098 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:8814098 | pubmed:dateCreated | 1996-10-21 | lld:pubmed |
| pubmed-article:8814098 | pubmed:abstractText | This study was undertaken to evaluate the dose tolerability and safety of a chronic ascending twice-daily (b.i.d.) dosage regimen of < or = 700 mg/day lamotrigine (LTG) and to include determination of the LTG pharmacokinetic profile at doses > or = 500 mg/day in patients receiving concomitant enzyme-inducing antiepileptic drugs (AEDs). | lld:pubmed |
| pubmed-article:8814098 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8814098 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8814098 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8814098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8814098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8814098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8814098 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8814098 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8814098 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:8814098 | pubmed:issn | 0013-9580 | lld:pubmed |
| pubmed-article:8814098 | pubmed:author | pubmed-author:MatsueHH | lld:pubmed |
| pubmed-article:8814098 | pubmed:author | pubmed-author:RisnerM EME | lld:pubmed |
| pubmed-article:8814098 | pubmed:author | pubmed-author:RollinsD EDE | lld:pubmed |
| pubmed-article:8814098 | pubmed:author | pubmed-author:MoeC RCR | lld:pubmed |
| pubmed-article:8814098 | pubmed:author | pubmed-author:HEL | lld:pubmed |
| pubmed-article:8814098 | pubmed:author | pubmed-author:TolmanK GKG | lld:pubmed |
| pubmed-article:8814098 | pubmed:author | pubmed-author:MadsenJJ | lld:pubmed |
| pubmed-article:8814098 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8814098 | pubmed:volume | 37 | lld:pubmed |
| pubmed-article:8814098 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8814098 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8814098 | pubmed:pagination | 857-62 | lld:pubmed |
| pubmed-article:8814098 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:meshHeading | pubmed-meshheading:8814098-... | lld:pubmed |
| pubmed-article:8814098 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8814098 | pubmed:articleTitle | Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study. | lld:pubmed |
| pubmed-article:8814098 | pubmed:affiliation | Department of Neurology, University of Utah School of Medicine, Salt Lake City 84132, USA. | lld:pubmed |
| pubmed-article:8814098 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8814098 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8814098 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8814098 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8814098 | lld:pubmed |
